VA, Kaiser partner to improve data sharing

The Veterans Health Administration (VA) and Kaiser Permanente (KP) will pool their resources to research and share best practices.

The organizations announced the Veterans Affairs Center of Innovation Partnership Program, which will focus on connected health and virtual care, genomics, VA and KP patients and advanced analytics to leverage innovative uses of large datasets and population management.

"We are eager to continue to redesign the experience of our veterans seeking healthcare to increase ease of access and quality of services," said Patrick Littlefield, director of the VA Center for Innovation, in a release. "We're excited about this partnership to make way for useful and tangible outputs."

In 2010, KP and VA launched a pilot program to exchange medical data using the Nationwide Health Information Network. The pilot allows clinicians from both organizations to obtain a more comprehensive view of a patient's health record using EHR information, and led to the VA exchange capability now available at 121 VA medical center locations nationwide with 14 private partners.

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.